1 / 18

2-3. Pharmaceutical Development

2-3. Pharmaceutical Development. Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014. May 18-21,2014. Outline. Focus on immediate release solid dosage forms Guidance Elements Case Studies. May 18-21,2014. TRS970 Annex 4. Overarching Principles:

aconnors
Download Presentation

2-3. Pharmaceutical Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014

  2. Outline • Focus on immediate release solid dosage forms • Guidance • Elements • Case Studies May 18-21,2014

  3. TRS970 Annex 4 • Overarching Principles: • The Pharmaceutical development section should contain information on the development studies conducted to establish that the dosage form, the formulation, manufacturing process, container-closure system, microbiological attributes and usage instructions are appropriate for the purpose specified in the product dossier. • Additionally, this section should identify and describe the formulation and process attributes (critical parameters) that can influence batch reproducibility, product performance and FPP quality. May 18-21,2014

  4. TRS970 Annex 4/ICH Q8 • Define Quality Target Product Profile (QTPP) as it relates to quality, safety and efficacy considering, for example, the route of administration, dosage form, bioavailability, strength and stability; • Identify Critical Quality Attributes (CQA) of the FPP so as to adequately control the product characteristics that could have an impact on quality; • Discuss CQAs of the API(s), excipients and container-closure system(s)including the selection of the type, grade and amount to deliver drug product of the desired quality; • Discuss the selection criteria for the manufacturing process and the control strategy required to manufacture commercial lots meeting the QTPP in a consistent manner. May 18-21,2014

  5. QTTP & CQA • Define Quality Target Product Profile (QTPP) as it relates to quality, safety and efficacy considering, for example, the route of administration, dosage form, bioavailability, strength and stability; • Identify Critical Quality Attributes (CQA) of the FPP so as to adequately control the product characteristics that could have an impact on quality; • Discuss CQAs of the API(s), excipients and container-closure system(s) including the selection of the type, grade and amount to deliver drug product of the desired quality; • Discuss the selection criteria for the manufacturing process and the control strategy required to manufacture commercial lots meeting the QTPP in a consistent manner May 18-21,2014

  6. QTPP & CQA • QTPP: A prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product. • CQA: A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. May 18-21,2014

  7. Case Study #1 • Identify the QTPPs and CQAs in the following table (product: 100mg IR tablets) May 18-21,2014

  8. TRS970 Annex 4/ICH Q8 • Define Quality Target Product Profile (QTPP) as it relates to quality, safety and efficacy considering, for example, the route of administration, dosage form, bioavailability, strength and stability; • Identify Critical Quality Attributes (CQA) of the FPP so as to adequately control the product characteristics that could have an impact on quality; • Discuss CQAs of the API(s), excipients and container-closure system(s)including the selection of the type, grade and amount to deliver drug product of the desired quality; • Discuss the selection criteria for the manufacturing process and the control strategy required to manufacture commercial lots meeting the QTPP in a consistent manner May 18-21,2014

  9. CQAs of the API & Excipients • Key physicochemical characteristics of the API that can influence the performance of the FPP: • Physical properties: particle size distribution, bulk and tap densities, crystalline form, hygroscopicity, solubility ; • Chemical properties: stability under temperature, humidity, oxidative, photolytic conditions • Biological properties: permeability, partition coefficient, BCS • The compatibility of the API(s) with each other (FDCs) and with excipients; • The choice of excipients, their concentration and their characteristics that can influence the FPP performance. May 18-21,2014

  10. Processes Wet granulation Dry Granulation Direct Compression Milling Milling Milling Pre-blending Pre-blending Blending/lubrication Addition of binder Slugging/Roller Compaction Screening wet mass Dry screening Drying Screening of granules Blending of lubricant Blending of lubricant Tablet compressionTablet Compression Tablet Compression What happens to the API May 18-21,2014

  11. CQA of the C/C System • Rationale for selection of the container closure system • Suitability of the container closure system for storage and transportation, including the storage and shipping container for bulk PP • Safety of packaging materials • Protection from moisture and light • Compatibility of the FPP with packaging materials May 18-21,2014

  12. TRS970 Annex 4/ICH Q8 • Define Quality Target Product Profile (QTPP) as it relates to quality, safety and efficacy considering, for example, the route of administration, dosage form, bioavailability, strength and stability; • Identify Critical Quality Attributes (CQA) of the FPP so as to adequately control the product characteristics that could have an impact on quality; • Discuss CQAs of the API(s), excipients and container-closure system(s)including the selection of the type, grade and amount to deliver drug product of the desired quality; • Discuss the selection criteria for the manufacturing process and the control strategy required to manufacture commercial lots meeting the QTPP in a consistent manner. May 18-21,2014

  13. Manufacturing Process Development • Justification for the selection of the manufacturing process and in-process controls; • Appropriateness of the equipment used; • Identification of critical process parameters (CPP) • Justification for differences between the manufacturing processes used to produce batches for bioequivalence studies or primary stability studies and the commercial process. May 18-21,2014

  14. Critical Process Parameter (CPP) • A process parameter whose variability has an impact on a critical quality attribute (CQA) and therefore should be monitored or controlled to ensure the process produces the desired quality • Blending • Granulation • Drying (LOD) • Compression • Coating May 18-21,2014

  15. Other Considerations • Justification for overages • Issues surrounding score line - uniformity testing (i.e. Content uniformity for split portions containing less than 5 mg or less than 5% of the weight of the dosage unit portion, or mass uniformity for other situations) should be performed on each split portion from a minimum of 10 randomly selected whole tablets. • In-vitro dissolution • Development of discriminatory method • Generation of dissolution profiles • Optimization and Scale-up May 18-21,2014

  16. Optimization Studies • Studies are undertaken to optimize: • quantity of binder • quantity of disintegrant • LOD • Different trial batches having varying amounts of disintegrant and binder are used; • Results of granule flowability, tablet characteristics and comparative dissolution profiles are compared; • Granules with different LOD levels are compressed and results with respect to flowability and tablet characteristics are used to finalize formulation; • The formulation so developed is considered to be optimized when there are no problems (e.g. capping) and the dissolution profile matches the innovator product May 18-21,2014

  17. Case Study #2 • Applicant has developed an IR tablet product containing light and moisture sensitive API. The API belongs to BCS class 2 and exists in 2 polymorphic forms. The API constitutes 4% of the formulation. The SmPC reports that the tablets are uncoated and scored bisected May 18-21,2014

  18. Thanks Questions ? May 18-21,2014

More Related